Onconova Therapeutics, Inc.
375 Pheasant Run
Newtown, PA 18940
November 13, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|
Attention: |
Paul Fischer Celeste M. Murphy |
|
|
|
|
Re: |
Onconova Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-234360 Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Onconova Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended (the “Registration Statement”), so that the Registration Statement may become effective at 12:00 p.m. (Eastern Time) on November 15, 2019, or as soon as practicable thereafter.
Once the Registration Statement has been declared effective, please orally confirm that event with Joanne R. Soslow of Morgan, Lewis & Bockius LLP at (215) 963-5262.
Under separate cover, you will receive today a letter from the underwriter of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
|
ONCONOVA THERAPEUTICS, INC. |
| |
|
|
|
|
|
|
|
|
|
By: |
/s/ MARK GUERIN |
|
|
|
|
|
|
Name: |
Mark Guerin |
|
|
|
|
|
|
Title: |
Chief Financial Officer |
|